Empresa Alnylam Pharmaceuticals, Inc. Sao Paulo
Acciones
A1LN34
BRA1LNBDR003
Biotecnología e investigación médica
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
42,94 BRL | +1,59 % |
|
+12,11 % | -3,83 % |
Resumen de negocios
Número de empleados: 2 100
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Ribonucleic Acid Interference Therapeutics
100,0
%
| 1 037 | 100,0 % | 1 828 | 100,0 % | +76,23 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
69,8
%
| 616 | 59,4 % | 1 276 | 69,8 % | +107,21 % |
Europe
21,8
%
| 315 | 30,4 % | 399 | 21,8 % | +26,83 % |
Rest of the World
8,4
%
| 107 | 10,3 % | 153 | 8,4 % | +43,31 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 61 | 19/09/16 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 13/08/19 |
Piyush Sharma
CMP | Compliance Officer | - | 21/09/22 |
Chief Tech/Sci/R&D Officer | - | 01/08/17 | |
Kevin Fitzgerald
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/01/05 |
James Bilotta
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/15 |
Pushkal Garg
CTO | Chief Tech/Sci/R&D Officer | 56 | 29/10/14 |
Joshua Brodsky
IRO | Public Communications Contact | - | 01/02/21 |
Investor Relations Contact | 43 | 01/09/15 | |
Eric Green
PRN | Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 18/12/15 |
Charles Sigal
BRD | Director/Board Member | 72 | 22/08/22 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 10/01/19 |
Amy Schulman
CHM | Chairman | 63 | 01/07/14 |
Phillip Sharp
FOU | Founder | 79 | 14/06/02 |
Peter Kellogg
BRD | Director/Board Member | 67 | 07/03/23 |
Michael Bonney
BRD | Director/Board Member | 65 | 17/12/14 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 23/04/12 |
Colleen Reitan
BRD | Director/Board Member | 64 | 01/06/18 |
Chief Executive Officer | 61 | 19/09/16 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 126 491 778 | 125 961 653 ( 99,58 %) | 0 | 99,58 % |
Información de la empresa
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street Henri A. Termeer Square
02142, Cambridge
+617 551 8200
http://www.alnylam.com![Dirección Alnylam Pharmaceuticals, Inc.(A1LN34)](https://cdn.zonebourse.com/static/address/119084101.png)
Sector
Ventas por región
![Consenso](/images/consensus_flch.gif)
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+40,80 % | 53,67 mil M | |
-8,05 % | 38,76 mil M | |
+35,79 % | 38,86 mil M | |
-8,98 % | 27,27 mil M | |
+10,69 % | 25,91 mil M | |
+31,00 % | 12,78 mil M | |
+28,51 % | 12,18 mil M | |
-1,67 % | 11,96 mil M | |
-11,39 % | 10,79 mil M |
- Bolsa de valores
- Acciones
- Acción ALNY
- Acción A1LN34
- Empresa Alnylam Pharmaceuticals, Inc.